Profile data is unavailable for this security.
About the company
Biotest AG is a Germany-based provider of plasma proteins and biological drugs. The Company, with a chain that extends from pre-clinical and clinical development to worldwide marketing and distribution, mainly specializes in the areas of clinical immunology, hematology, and intensive care medicine. It develops, manufactures, and markets immunoglobulin, coagulation factors, and albumins based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. In addition, the Company develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus, which are produced by recombinant technologies.
- Revenue in EUR (TTM)684.60m
- Net income in EUR127.00m
- Incorporated2006
- Employees2.43k
- LocationBiotest AGLandsteinerstr. 5DREIEICH 63303GermanyDEU
- Phone+49 61038010
- Fax+49 6 103801150
- Websitehttps://www.biotest.com/
More ▼
Holder | Shares | % Held |
---|---|---|
Ersel Asset Management SGR SpAas of 30 Jun 2023 | 196.34k | 0.99% |
FPS Verm�gensverwaltung GmbHas of 30 Jun 2023 | 102.19k | 0.52% |
Knoesel & Ronge Verm�gensverwaltung GmbH & Co. KGas of 28 Feb 2023 | 46.00k | 0.23% |
Banor Capital Ltd.as of 30 Nov 2021 | 9.07k | 0.05% |
SSgA Funds Management, Inc.as of 04 Apr 2024 | 214.00 | 0.00% |
BANTLEON Invest GmbHas of 30 Nov 2023 | 0.00 | 0.00% |
TBF Global Asset Management GmbHas of 31 Dec 2022 | 0.00 | 0.00% |
Axxion SA (Luxembourg)as of 31 Mar 2023 | 0.00 | 0.00% |
More ▼
Data from 28 Feb 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.